WALDENSTROM MACROGLOBULINEMIA

This early-phase trial tests an oral drug called AS-1763 in adults with certain blood cancers (like CLL or lymphoma) that have not responded to at least two prior treatments. The main goals are to find the safest dose and see if the drug can shrink tumors. Around 120 participants…

This study offers ongoing access to the drug ibrutinib for people with certain blood cancers (like chronic lymphocytic leukemia or mantle cell lymphoma) who are already taking it and benefiting. Researchers will track side effects and disease changes over time. About 700 particip…

This study is for people with certain blood cancers (like CLL or lymphoma) who are starting a type of drug called a BTK inhibitor. These drugs can raise blood pressure and increase the risk of heart problems. The study will test if carefully managing high blood pressure can lower…

This study tests a drug called epcoritamab in 20 people with Waldenstrom macroglobulinemia, a rare blood cancer, that has already been treated. The drug is a type of antibody that helps the immune system attack cancer cells. The main goal is to see how many patients respond to th…

This early-phase study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to recognize and attack cancer cells. The main…

This study compares three treatment approaches for people with previously untreated Waldenstrom's macroglobulinemia, a rare blood cancer. About 92 participants will receive either a combination of venetoclax and rituximab, or one of two other targeted therapies (ibrutinib plus ri…

This study tests a time-limited combination of three drugs (pirtobrutinib, venetoclax, and rituximab) in 40 adults newly diagnosed with Waldenström's macroglobulinemia, a rare blood cancer. The goal is to see if this treatment can achieve a very good partial response or better. P…

This early-phase study is testing an experimental oral drug called LP-168 in about 60 people with certain blood cancers (like CLL, lymphoma, and Waldenstrom macroglobulinemia) that have returned or not responded to prior therapies. The main goals are to find the safest dose and u…

This early-phase study tests a new drug called SGR-1505 in about 98 adults with various B-cell blood cancers (like lymphoma and leukemia). The main goals are to check safety and find the best dose. Participants will receive the drug and be monitored for side effects and how the d…

This study tests a drug called venetoclax in about 14 Japanese adults with a rare blood cancer (Waldenström macroglobulinemia) that has returned or stopped responding to prior therapy. Participants take venetoclax pills daily, with doses slowly increased to a target level. The ma…

This study tests whether combining three drugs—zanubrutinib, bendamustine, and rituximab—can achieve a very good partial response or better in people with untreated Waldenström macroglobulinemia, a rare blood cancer. About 55 participants will receive the combination therapy. The…

This study tests whether a combination of two drugs, venetoclax and rituximab, works better than standard chemotherapy for people with untreated Waldenström's macroglobulinemia, a rare blood cancer. About 80 participants will receive either the drug combo or chemo, and researcher…

This study is looking at how well the drug zanubrutinib works and how safe it is for people with Waldenström macroglobulinemia, a rare type of blood cancer. Researchers will track 111 participants from different racial and ethnic backgrounds, including those with specific genetic…

This study follows up to 1,000 adults with certain blood cancers (CLL, SLL, LPL, or WM) to learn how these diseases change over time. Participants get regular check-ups, blood tests, and optional scans or biopsies, but no treatment is given. The goal is to better understand the d…

This study looks at genetic changes in people with early-stage blood cancers or conditions that may lead to cancer. Researchers want to understand why some cases progress and others don't. Participants provide extra blood, bone marrow, or cheek swab samples during routine care. N…

This study aims to create a national registry of patients in Spain diagnosed with Waldenström macroglobulinemia or a related condition called IgM-MGUS over the past 30 years. Researchers will collect information from medical records to understand the disease's features, treatment…

This study involves 90 people with Waldenström Macroglobulinemia, a rare blood cancer. Researchers want to see if detecting tumor DNA in the blood after 6 months of treatment can predict whether the cancer will come back within 3 years. Participants give blood samples and are fol…